FDG PET/CT and Dosimetric Studies of (177)Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma—Are We Hitting the Target?

PURPOSE: [(177)Lu]Lu-lilotomab satetraxetan, a novel CD37 directed radioimmunotherapy (RIT), has been investigated in a first-in-human phase 1/2a study for relapsed indolent non-Hodgkin lymphoma. In this study, new methods were assessed to calculate the mean absorbed dose to the total tumor volume,...

Descripción completa

Detalles Bibliográficos
Autores principales: Løndalen, Ayca, Blakkisrud, Johan, Revheim, Mona-Elisabeth, Dahle, Jostein, Kolstad, Arne, Stokke, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581842/
https://www.ncbi.nlm.nih.gov/pubmed/35486292
http://dx.doi.org/10.1007/s11307-022-01731-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581842/
https://www.ncbi.nlm.nih.gov/pubmed/35486292
http://dx.doi.org/10.1007/s11307-022-01731-3

Ejemplares similares